Skip to main content
SP5007,785.76-0.17%DOW53,732.41-0.20%NASDAQ26,729.16-0.28%BTC$62,945.00-0.85%ETH$1,880.32-0.35%GOLD$4,432.00+0.26%OIL$82.40+1.42%
Smart Investors Daily
Sign InSign Up Free
IV

OTC · IVRO

InVitro International

Healthcare · Medical - Diagnostics & Research

$0.05

Up+$0.00 (+0.00%)

Updated Aug 16, 2026, 11:38 AM

SID Score

3.3/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
2.26M
P/E ratio
18.64
Dividend yield
0.00%
52-week range
$0.03 – $0.16
Volume
6.1K
Avg. volume
12.21K

Price performance

IVRO price history

1M range · 9 trading sessions · Daily adjusted prices

IVRO closed at $0.05 after 9 trading sessions, down 39.80% for the selected period.

Last close
$0.05
Period change
-39.80%
Period low
$0.05
Period high
$0.08
Daily close
View OHLC price history
IVRO OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Aug 13, 2026$0.0486$0.0622$0.0486$0.0496.1K
Aug 12, 2026$0.0517$0.058$0.0452$0.058127.08K
Aug 11, 2026$0.0611$0.0611$0.0475$0.0515114.57K
Aug 3, 2026$0.0679$0.0679$0.0679$0.06791.9K
Jul 30, 2026$0.067$0.067$0.067$0.0677K
Jul 29, 2026$0.062$0.062$0.062$0.0628.58K
Jul 28, 2026$0.0681$0.0681$0.062$0.062990
Jul 24, 2026$0.0611$0.0611$0.0611$0.0611130
Jul 21, 2026$0.0609$0.0814$0.0609$0.08144.35K

Latest IVRO news

The latest Smart Investors Daily articles mentioning IVRO.

Stock researchCompany · Overview

IVRO research

Overview

Company profile and research snapshot.

Company profile

INVITRO INTL

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Dec 9, 2025

Game Changing Signals from Global Regulatory Agencies Accompany IVRO Sales and Profit Gains

Placentia, California--(Newsfile Corp. - December 9, 2025) - Today, InVitro International (OTCQB: IVRO) reported FY '25 sales of $878,937, up 8.3% over FY '24. Net income of $121,980 advanced 14.3% for the same period. CEO and Chairman, W. Richard Ulmer, offered his view of IVRO's progress: "In this past year, Regulatory Agencies around the world announced they have already, or will soon, cease funding for animal testing; some have stopped now. Further, some RA's state OECD validated NON-animal.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By